Bailard’s Palvella Therapeutics PVLA Stock Holding History

Bailard’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-245	Closed	-$59K	–	820
2022 Q1	$59K	Buy	+245	New	+$64.4K	﹤0.01%	709

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bailard's PVLA Position: Q2 2022 in Review

Bailard sold out of Palvella Therapeutics (PVLA) in Q2 2022, closing a stake of 245 shares — an estimated $59K sold.

Bailard first reported a position in PVLA in Q1 2022 and held it in 1 quarter. The position peaked at $59K in Q1 2022. 68 funds tracked by Wall St. Rank hold PVLA as of Q2 2022.

Bailard reported no remaining Palvella Therapeutics position as of Q2 2022 after selling out during the quarter.
Bailard sold 245 Palvella Therapeutics shares in Q2 2022, an estimated $59K.
Bailard first reported a position in Palvella Therapeutics in Q1 2022 and held it in 1 quarter.
Bailard's Palvella Therapeutics position peaked at $59K in Q1 2022.
68 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.